ACAD

Business Context and Reporting Period

Company: Acadia Pharmaceuticals Inc. (ACAD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Acadia is a biopharmaceutical company focused on neurological and rare diseases. Its core franchises are anchored by NUPLAZID (pimavanserin) for Parkinson's disease psychosis (PDP) and DAYBUE (trofinetide) for Rett syndrome. The company operates as a single business segment.

Key Financial Metrics (Year Ended Dec 31, 2025)

Product Sales Breakdown (2025):
- NUPLAZID: $680.1 million
- DAYBUE: $391.4 million

Material Changes vs. Prior Period

• Revenue Growth: Net product sales increased 11.9% driven by unit sales growth and higher average net selling prices for both NUPLAZID and DAYBUE.
• Operating Income Decline: Despite revenue growth, operating income decreased significantly (from $230.8M to $104.8M). This was primarily due to the absence of the $146.5 million "Gain on sale of non-financial asset" (Priority Review Voucher) recorded in 2024, alongside increased R&D and SG&A expenses.
• Net Income Increase: Net income rose to $391.0 million, largely due to a significant reduction in the valuation allowance against deferred tax assets ($249.9 million benefit) after achieving three years of cumulative profitability.
• Rebate Adjustment: Net sales were reduced by an unfavorable change in estimate of approximately $11.8 million related to Medicare inflation cap rebates for prior periods (Oct 2022–Dec 2024).
• Expense Increases: SG&A increased due to consumer activation programs for NUPLAZID and expansion of the DAYBUE team. R&D increased due to expenditures for remlifanserin and early-stage candidates.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Pipeline

• NUPLAZID: Management aims to achieve $1.0 billion in net sales by 2028 through increased field force size and direct-to-consumer campaigns.
• DAYBUE: Growth is expected from new patient adoption and the launch of DAYBUE STIX (powder formulation) in Q2 2026. International expansion is ongoing, with approvals in Canada (2024) and Israel (2025).
• EU Regulatory Status: In January 2026, the EMA's CHMP issued a negative trend vote on the Marketing Authorization Application (MAA) for trofinetide in the EU. Acadia intends to request a re-examination, with a potential launch anticipated in Q3 2026 if approved.
• Pipeline: Phase 2 studies for remlifanserin (Alzheimer's/Lewy Body Dementia) and ACP-211 (Major Depressive Disorder) are ongoing. ACP-101 (Prader-Willi Syndrome) was discontinued in September 2025 after failing to meet primary endpoints.

Risks and Contingencies

• Regulatory Risk: The negative EMA trend vote for trofinetide poses a risk to international revenue projections. Post-marketing requirements (PMRs) for DAYBUE remain ongoing.
• Legal Proceedings:
  • Patent Litigation: Acadia won final judgments against MSN and Aurobindo regarding NUPLAZID patent infringement in June 2025; appeals are pending. A new suit against Zydus is scheduled for trial in November 2026.
  • Securities Litigation: A securities class action regarding the failed dementia-related psychosis trial is in pretrial motions. A derivative suit was settled in principle for $1.5 million in attorney fees (paid by insurance).
• Supply Chain: The company relies on third-party manufacturers. Tariffs and trade policies could increase costs, with limited ability to pass these costs to customers due to fixed pricing contracts.

Key Facts for Investor Verification

• EU Approval Status: Verify the outcome of the EMA CHMP re-examination for trofinetide (expected opinion in Feb 2026) as this is critical for international growth.
• Rebate Accruals: Monitor the accuracy of Medicare Part D inflation cap rebate accruals, given the $11.8M adjustment in 2025.
• Deferred Tax Assets: Confirm the sustainability of the $249.9 million deferred tax asset realization, which was a major driver of 2025 net income.
• Patent Expirations: Review the timeline for generic entry of NUPLAZID; current settlements delay generic launch until 2036/2038, but litigation outcomes could alter this.
• Operating Cash Flow: Note the 30% decline in operating cash flow despite revenue growth, driven by higher operating expenses and working capital changes.